Biohaven announced that its board has added an Infinitum founder and Groq board director, bringing frontier AI and technology-investing expertise as the company advances AI-enabled drug development approaches. The update is largely leadership/strategy-focused with no quantified financial or clinical milestones provided.
Biohaven announced that its board has added an Infinitum founder and Groq board director, bringing frontier AI and technology-investing expertise as the company advances AI-enabled drug development approaches. The update is largely leadership/strategy-focused with no quantified financial or clinical milestones provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
